Ocugen, Inc. · NASDAQ:OCGN
Ocugen — Q2 2024 Earnings Presentation
15 slides from Ocugen's earnings presentation, Aug 8, 2024
Slide 1: 2Q 2024 Business Update
—_—_ ~ ocugen. > ee Courageous Innovation Dedicated to Bringing Game-Changing Gene & Cell Therapies and Vaccines to Market and Working Even Harder to Provide Access to Patients Globally 2Q 2024 Business Update August 8, 2024
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of
Slide 3: Inclusion of Ocugen in the Russell Index
Inclusion of Ocugen in the Russell Index adds to what has a j ELL already been a transformational year for the Company gs AnLSEG
Slide 4: Modifier Gene Therapy - Creating a Paradigm Shift in Gene Therapy
Modifier Gene Therapy - Creating a Paradigm Shift in Gene Therapy ¥ First patient dosed inthe OCU400 Phase 3liMeliGhT clinical trial for retinitis pigmentosa (RP) On track for 2026 BLA and MAA approval targets Upcoming anticipated catalysts: * Clinical updates including Phase 3 recruitment for RP Fi
Slide 5: Mobility Test (LDNA) is Primary Endpoint for Phase 3
Mobility Test (LDNA*) is Primary Endpoint for Phase 3 * Primary endpoint (Efficacy): Mobility test has been used for an approved product * Alignment with FDA to demonstrate clinical efficacy (Responder 2 2 Lux level improvement) - Validated for RP patients * Phase 1/2 results: More than 60% of the i
Slide 6: OCU400: RP Market Opportunity
OCU400: RP Market Opportunity OCU400is Messed) to address the shortcomings of current gene therapy approaches—a broad spectrum, gene- agnosticapproach to genetically diverse inherited retinal diseases and potential one-time therapy for life witha single sub-retinal injection Retinitis Pigmentosa (RP
Slide 7: OCU400 Expanded Access Program
OCU400 Expanded Access Program Available for patients 18 years + with early, intermediate to advanced RP with at least minimal retinal preservation who may benefit from the mechanism of action of OCU400 prior to approval of the Biologics License Application (BLA) First EAP for gene therapy candidate
Slide 8: OCU410 (Dry AMD): A Single-Injection Approach to Address Unmet Need
OCU410 (Dry AMD): A Single-Injection Approach to Address Unmet Need ¥ Completed Phase 1 of OCU410 Phase 1/2 ArMaDa clinical trial * Nine patients with GA have been dosed in the Phase 1/2 clinical trial (low, medium, and high dose) v Phase 2 clinical trial to assess the safety and efficacy of OCU410
Slide 9: OCU410 Program Overview—Phase 2
OCU410 Program Overview—Phase 2 Study Objective and Modality * Assess the safety and efficacy of OCU410 in subjects with geographic atrophy (GA) secondary to dry age- related macular degeneration (dAMD) * Single, unilateral subretinal injection using a modifier gene therapy platform Overall Strategy
Slide 10: OCU410ST (Stargardt Disease): Modifier Gene Therapy
OCU4I0ST (Stargardt Disease): Modifier Gene Therapy Addressing Shortcomings of Current Approaches ¥ Completing dosing with the high dose of OCU410ST in the dose-escalation phase of the clinical trial Upcoming anticipated catalyst: Preliminary safety and efficacy update from ongoing OCU410ST Phase 1/
Slide 11: Financial Update
Financial Update
Slide 12: Financial Update
Financial Update Statement of Operations Three months ended June 30, 2024 2023 Research and development expense $8.9 $14.5 General and administrative expense 77 9.5 Other income (expense), net 0.2 05 Net loss $(15.3) $(23.1) Net loss per share of common stock — basic and diluted $(0.04) $(0.10) Bala
Slide 13: Questions & Answers
Questions & Answers
Slide 14: 2024 Near-Term Targeted Milestones
2024 Near-Term Targeted Milestones OCU400 Phase 3 dosing and recruitment updates —- 2026 BLA/MAA approval targets on track Preliminary safety/efficacy updates - OCU410 Phase 1/2 clinical trial (GA) Preliminary safety/efficacy updates - OCU410ST Phase 1/2 clinical trial (Stargardt Disease) — ocugen.
Slide 15: Ocugen Vision
Ocugen™ Vision We're here to make an impact. At Ocugen, we approach drug development with a sense of urgency, resolve, ingenuity, and boldness. We consider patients in everything we do. Courageous innovation means driving science in new directions and breaking new ground. — ocugen. 6 —